Trial Profile
An Extended Study of CB7630 (Abiraterone Acetate) in Patients With Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy and Completed Clinical Study COU-AA-003 [EXTENSION OF 700025105]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Mar 2013
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Corticosteroids
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 05 Mar 2013 New trial record